Alnylampharmaceuticalsinc.gcs-web.com

Alnylam to Webcast Presentation at BofA Securities 2023 Health …

WebCAMBRIDGE, Mass.--(BUSINESS WIRE)--May 3, 2023-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, …

Actived: 2 days ago

URL: https://alnylampharmaceuticalsinc.gcs-web.com/news-releases/news-release-details/alnylam-webcast-presentation-bofa-securities-2023-health-care

Alnylam Announces Launch of “Alnylam Challengers,” a Signature

Web− Alnylam will provide a $1 Million Grant to Acumen America and will serve as an Anchor Partner of their Health Equity Portfolio –. CAMBRIDGE, Mass.- …

Category: Health Go Health

Alnylam to Webcast Presentation at BofA Securities 2023 …

Webannounced today that management will present a company overview at the BofA Securities 2023 Health Care Conference on Wednesday, May 10, 2023 at 1:40 pm PT (4:40 pm ET …

Category: Health Go Health

Alnylam to Present Additional Data for Patisiran in Patients With …

WebIn addition, findings from a post-hoc analysis of the APOLLO-B Phase 3 study that further characterize the impact of patisiran on health status and quality of life in …

Category: Health Go Health

Fourth Quarter and Full Year 2023 Financial Results

WebPatients: Over 0.5 million on Alnylam RNAi therapeutics globally Products: 6+ marketed products in rare and prevalent diseases Pipeline: Over 20 clinical programs, …

Category: Health Go Health

Alnylam Completes Enrollment in HELIOS-B Phase 3 Study of

Web− Full Study Enrollment Completed Well Ahead of Schedule −. CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 9, 2021-- Alnylam Pharmaceuticals, Inc. (Nasdaq: …

Category: Health Go Health

Alnylam Issues 2022 Corporate Responsibility Report

WebCAMBRIDGE, Mass. -- (BUSINESS WIRE)--May 3, 2023-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today …

Category: Health Go Health

First Set of Recommendations Advocating for the Holistic Care of …

WebThe international HCP-patient advocacy community endorsed 98% of the recommendations, which focussed on seven core areas aimed to improve patient care: …

Category: Health Go Health

Alnylam Initiates KARDIA-1 Phase 2 Study of Zilebesiran (ALN …

Web“According to the World Health Organization, hypertension is the largest modifiable risk factor for cardiovascular morbidity and mortality. Despite the availability of …

Category: Health Go Health

Alnylam Submits CTA Application for ALN-KHK, an Investigational …

WebThe safety and efficacy of ALN-KHK have not been evaluated by the FDA, EMA, Health Canada, or any other health authority. About Type 2 Diabetes Mellitus …

Category: Health Go Health

Alnylam Submits Supplemental New Drug Application (sNDA) to …

Web– sNDA Submission is Based on Findings from the APOLLO-B Phase 3 Study That Showed Patisiran Demonstrated Significant Improvement on Functional Capacity, …

Category: Health Go Health

Alnylam to Present Full 9-Month Results from the HELIOS-A Phase …

WebThe safety and efficacy of vutrisiran have not been evaluated by the U.S. Food and Drug Administration, European Medicines Agency or any other health …

Category: Food, Medicine Go Health

Alnylam Reports Positive Topline Results from KARDIA-1 Phase 2 …

Web“Hypertension is a growing global health crisis responsible for around 10 million deaths worldwide each year. Despite the availability of several classes of oral anti …

Category: Health Go Health

Alnylam Initiates KARDIA-2 Phase 2 Study of Investigational …

Webas an innovative potential treatment with an infrequent dosing regimen that could one day help address this global public health crisis. KARDIA-2 is the second Phase 2 study …

Category: Health Go Health

Alnylam Announces Publication of Results from APOLLO-B Phase …

WebResults from an interim analysis of the ongoing OLE period of the APOLLO-B Phase 3 study were recently presented at the Heart Failure Society of America (HFSA) …

Category: Health Go Health

Novartis and Alnylam Announce New Collaboration to Develop …

WebThe World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC) have expressed major concern about the potential for this virus to mutate into a …

Category: Health Go Health

New Clinical Results with Fitusiran

WebFitusiran is an investigational medicine. Its safety and efficacy have not been established by any health authorities. Phase 2 OLE‡ (n= 33) • Individual patient dose adjustment may …

Category: Medicine Go Health

Code of Business Conduct and Ethics

WebHarnessing a Revolution in Biology for Human Health Our Mission Build a top-tier, independent biopharmaceutical company founded on RNAi Our Core Values Core …

Category: Health Go Health

Alnylam Submits CTA Application for ALN-XDH, an Investigational …

WebThe safety and efficacy of ALN-XDH have not been evaluated by the FDA, EMA, or any other health authority. About Gout. Gout is the most common form of …

Category: Health Go Health

Alnylam to Webcast Presentation at Banc Of America Securities …

WebAlnylam to Webcast Presentation at Banc Of America Securities 'New Products, New Paradigms In Health Care' Conference on July 29, 2004. CAMBRIDGE, Mass., Jul 23, …

Category: Health Go Health